Kim Young Dae, Heo Ji Hoe, Yoo Joonsang, Park Hyungjong, Kim Byung Moon, Bang Oh Young, Kim Hyeon Chang, Han Euna, Kim Dong Joon, Heo JoonNyung, Kim Minyoung, Choi Jin Kyo, Lee Kyung-Yul, Lee Hye Sun, Shin Dong Hoon, Choi Hye-Yeon, Sohn Sung-Il, Hong Jeong-Ho, Baek Jang-Hyun, Kim Gyu Sik, Seo Woo-Keun, Chung Jong-Won, Kim Seo Hyun, Song Tae-Jin, Han Sang Won, Park Joong Hyun, Kim Jinkwon, Jung Yo Han, Cho Han-Jin, Ahn Seong Hwan, Lee Sung Ik, Seo Kwon-Duk, Nam Hyo Suk
Department of Neurology, Yonsei University College of Medicine, Seoul 03722, Korea.
Department of Neurology, Brain Research Institute, Keimyung University School of Medicine, Daegu 41931, Korea.
J Clin Med. 2020 Mar 6;9(3):717. doi: 10.3390/jcm9030717.
We investigated whether there was an annual change in outcomes in patients who received the thrombolytic therapy or endovascular treatment (EVT) in Korea. This analysis was performed using data from a nationwide multicenter registry for exploring the selection criteria of patients who would benefit from reperfusion therapies in Korea. We compared the annual changes in the modified Rankin scale (mRS) at discharge and after 90 days and the achievement of successful recanalization from 2012 to 2017. We also investigated the determinants of favorable functional outcomes. Among 1230 included patients, the improvement of functional outcome at discharge after reperfusion therapy was noted as the calendar year increased ( < 0.001). The proportion of patients who were discharged to home significantly increased (from 45.6% in 2012 to 58.5% in 2017) ( < 0.001). The successful recanalization rate increased over time from 78.6% in 2012 to 85.1% in 2017 ( = 0.006). Time from door to initiation of reperfusion therapy decreased over the years ( < 0.05). These secular trends of improvements were also observed in 1203 patients with available mRS data at 90 days ( < 0.05). Functional outcome was associated with the calendar year, age, initial stroke severity, diabetes, preadmission disability, intervals from door to reperfusion therapy, and achievement of successful recanalization. This study demonstrated the secular trends of improvement in functional outcome and successful recanalization rate in patients who received reperfusion therapy in Korea.
我们调查了在韩国接受溶栓治疗或血管内治疗（EVT）的患者的预后是否存在年度变化。该分析使用了来自全国多中心登记处的数据，以探索韩国可能从再灌注治疗中获益的患者的选择标准。我们比较了2012年至2017年出院时和90天后改良Rankin量表（mRS）的年度变化以及成功再通的实现情况。我们还研究了良好功能预后的决定因素。在1230名纳入患者中，随着日历年的增加，再灌注治疗后出院时功能预后的改善情况显著（<0.001）。出院回家的患者比例显著增加（从2012年的45.6%增至2017年的58.5%）（<0.001）。成功再通率随时间从2012年的78.6%增至2017年的85.1%（=0.006）。从入院到开始再灌注治疗的时间逐年减少（<0.05）。在1203名90天时有可用mRS数据的患者中也观察到了这些长期改善趋势（<0.05）。功能预后与日历年、年龄、初始卒中严重程度、糖尿病、入院前残疾情况、从入院到再灌注治疗的时间间隔以及成功再通情况相关。本研究证明了韩国接受再灌注治疗的患者在功能预后和成功再通率方面的长期改善趋势。
